NCT02745561

Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.

A Phase II Study of Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 22 (estimated)
• Sponsor: Hangzhou Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Endostatin inhibits the pro-angiogenic action of basic fibroblast growth factor and vascular endothelial growth factor in esophageal cancer.This study aims at assessing the efficacy and safety of endostatin combined with concurrent chemoradiotherapy with Oxaliplatin in esophageal cancer patients.

Conditions

• Esophageal Cancer
• Endostatin

Interventions

Type	Name	Description
DRUG	Endostatins	Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy.
DRUG	Oxaliplatin	Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.
RADIATION	Radiotherapy	Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks.

Timeline

• Start date: 2016-01-01
• Primary completion: 2017-12-01
• Completion: 2018-12-01
• First posted: 2016-04-20
• Last updated: 2016-04-20

Locations

1 site across 1 country: China